A Phase 3 interventional study of JW0108 + C2407 and JW0108 + C2407 placebo in Dyslipidemia, sponsored by JW Pharmaceutical. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by JW Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Dyslipidemias with a site in Korea, Republic of — 30 open to participants now, 39 under way, 5 of them phase 3. Dyslipidemias · Korea, Republic of.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, this one is the 44th largest by enrollment of the 124 interventional ones that give a count, is one of 14 that started in 2025, is one of 31 in phase 3, and was the 133rd registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →30 of the 155 studies in Dyslipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19–54 · Healthy volunteers
Yonsei University · Sites in Korea, Republic of
Ages 19–85
Sin Gon Kim · Sites in Korea, Republic of
Ages 70+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Korea United Pharm. Inc. · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 100 across 987 interventional studies indexed under Dyslipidemias.
Median enrollment 80 across the 124 interventional studies, 5,000 across the 31 observational. Of the 99 that completed or were terminated, 3 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 155 have an industry lead sponsor. The 10 most frequent:
JW Pharmaceutical is the lead sponsor of 77 studies on the registry; 6 are open to participants now.
JW Pharmaceutical has 6 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
6 of the studies in Dyslipidemias with a site in Korea, Republic of that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07523971JW PharmaceuticalEfficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study | 2026-12 |
| NCT05365425Seoul National University Bundang HospitalCholine Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT05365438Seoul National University Bundang HospitalAtmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia | 2026-12-31 |
| NCT06293417Korea University Anam HospitalTo Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM | 2027-02-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 155 studies in Dyslipidemias with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients with Dyslipidemia
To evaluate the efficacy and safety of JW0108+C2407 in dyslipidemia patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For 8weeks QD(Quaque Die)
Drug: JW0108 + C2407
For 8weeks QD(Quaque Die)
Drug: JW0108 + C2407 placebo
JW0108 + C2407
JW0108 + C2407 placebo
Percent change from baseline in LDL-C
Check LDL-C
Time frame: Week 8
Efficacy and Safety: Change from baseline in LDL-C (mg/dL)
Check LDL-C
Time frame: Week 8
Ran from Apr 2025 to primary completion in Jul 2025, 3 months.
Of 52 industry-sponsored phase 3 interventional studies under Dyslipidemias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 3 months is below that.
Counting every sponsor, half of 62 studies reached it within 22 months; a quarter within 12 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.